E-LIB Suche - Ergebnisse für: Callahan, Margaret K.

1

A topic modeling approach reveals the dynamic T cell compos..:

Peng, Xiyu ; Lee, Jasme ; Adamow, Matthew...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475788/. , 2023

2

Nivolumab and Relatlimab in Patients With Advanced Melanoma..:

Ascierto, Paolo Antonio ; Lipson, Evan J ; Dummer, Reinhard...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431305/. , 2023

Link: http://www.ncbi.nlm.nih...

3

Phase Ib Trial of Phenformin in Patients with V600-mutated ..:

Chapman, Paul B ; Klang, Mark ; Postow, Michael A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695100/. , 2023

Link: http://www.ncbi.nlm.nih...

4

Uncovering the hidden structure of dynamic T cell compositi..:

Peng, Xiyu ; Lee, Jasme ; Adamow, Matthew...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168231/. , 2023

Link: http://www.ncbi.nlm.nih...

5

Decision-Making and Health-Related Quality of Life in Patie..:

Atkinson, Thomas M ; Hay, Jennifer L ; Young Kim, Soo...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078893/. , 2023

Link: http://www.ncbi.nlm.nih...

6

Fundamental immune–oncogenicity trade-offs define driver mu..:

Hoyos, David ; Zappasodi, Roberta ; Schulze, Isabell...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159948/. , 2022

Link: http://www.ncbi.nlm.nih...

7

First in Human Phase 1/2 ICONIC Trial of the ICOS agonist v..:

Yap, Timothy A ; Gainor, Justin F ; Callahan, Margaret K...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433959/. , 2022

Link: http://www.ncbi.nlm.nih...

8

Author Correction: Fundamental immune–oncogenicity trade-of..:

Hoyos, David ; Zappasodi, Roberta ; Schulze, Isabell...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200628/. , 2022

Link: http://www.ncbi.nlm.nih...

9

Safety, tolerability and efficacy of agonist anti-CD27 anti..:

Sanborn, Rachel E ; Pishvaian, Michael J ; Callahan, Margaret K...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364417/. , 2022

Link: http://www.ncbi.nlm.nih...

10

Tumor MHC Class I Expression Associates with Intralesional ..:

Pourmaleki, Maryam ; Jones, Caitlin J ; Ariyan, Charlotte E...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898286/. , 2022

Link: http://www.ncbi.nlm.nih...

11

Fundamental immune–oncogenicity trade-offs define driver mu..:

Hoyos, David ; Zappasodi, Roberta ; Schulze, Isabell...
https://orbit.dtu.dk/en/publications/2cecfe83-83f8-43ee-9ba8-4b209033cd0c. , 2022

Link: https://orbit.dtu.dk/en/..

12

PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF a..:

Callahan, Margaret K ; Chapman, Paul B
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061142/. , 2022

Link: http://www.ncbi.nlm.nih...

13

Apples and Oranges? Considerations for EHR-Based Analyses A..:

Lavery, Jessica A ; Callahan, Margaret K ; Panageas, Katherine S
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240792/. , 2021

Link: http://www.ncbi.nlm.nih...

14

Inherited PD-1 deficiency underlies tuberculosis and autoim..:

Ogishi, Masato ; Yang, Rui ; Aytekin, Caner...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446316/. , 2021

Link: http://www.ncbi.nlm.nih...

15

Therapeutic Implications of Detecting MAP Kinase Activating..:

Shoushtari, Alexander N ; Chatila, Walid K ; Arora, Arshi...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046739/. , 2021

Link: http://www.ncbi.nlm.nih...